NEW YORK – Single-cell analysis firm Cytek Biosciences said on Tuesday that its board of directors has approved a stock repurchase program for up to $50 million of its common stock for 2025. It will succeed an existing $50 million stock repurchase program that expires on Dec. 31.
The new program will commence on Jan. 1, 2025, and it will remain in effect until Dec. 31, 2025, unless extended or shortened by the board of directors, the company said.
Any repurchases under the 2025 program will be made in the open market or in privately negotiated transactions, according to the firm.